Transcatheter valvular interventions in 2017: some things old, some things new!

被引:0
|
作者
Rehman, Hasan [1 ]
Kleiman, Neal S. [1 ]
Kalra, Ankur [2 ]
机构
[1] Houston Methodist Hosp, Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA
[2] Case Western Reserve Univ, Sch Med, Dept Med,Div Cardiovasc Med, Univ Hosp Cleveland Med Ctr,Harrington Heart & Va, 11100 Euclid Ave,Mailstop LKS 5038, Cleveland, OH 44106 USA
关键词
bicuspid aortic valves; mitral valve repair; mitral valve replacement; transcatheter aortic valve replacement; valve leaflet thrombosis; AORTIC-VALVE-REPLACEMENT; MITRAL REGURGITATION; LEAFLET THROMBOSIS; IMPLANTATION; RISK; MULTICENTER; STENOSIS;
D O I
10.1097/HCO.0000000000000531
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Transcatheter valvular interventions have changed the landscape of valvular therapies. We examine some studies on transcatheter valvular interventions published in the year 2017 to better understand their implications on clinical practice and future research. Recent findings Findings from the SURTAVI study suggest TAVR to be a reasonable option in intermediate risk patients with aortic stenosis. Recent studies indicate that valve leaflet thrombosis is associated with poor outcomes. Data from the TVT registry on current transcatheter mitral valve repair are encouraging; alternative repair systems have been subjected to feasibility trials. TAVR for patients with bicuspid aortic valve stenosis appears to be improving. Cerebral embolic protection devices have shown promise but the population in whom they are most likely to provide benefit needs to be better defined. Summary The year 2017 has seen significant advances in the field of transcatheter valvular interventions. Strong foundations have been laid for future studies that are likely to significantly impact clinical practice.
引用
收藏
页码:363 / 368
页数:6
相关论文
共 50 条